You are here

Article Text

Article menu
Download PDFPDF
Editorial
Opportunities to improve surveillance for hepatocellular carcinoma in the UK
  1. Ian A Rowe
  1. Correspondence to Dr Ian A Rowe, University Academic Fellow and Honorary Consultant Hepatologist, Leeds Institute for Data Analytics, Room 6.12, Level 6, Clinical Sciences Building, University of Leeds, St James's Hospital, Leeds LS9 7TF, UK; i.a.c.rowe{at}leeds.ac.uk

https://doi.org/10.1136/flgastro-2015-100675

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Individuals with cirrhosis are at greatly increased risk of death from both liver failure and hepatocellular carcinoma (HCC). In this context, many specialist societies recommend using ultrasound surveillance to detect HCC early with the aim to reduce mortality from liver disease and not only from HCC.1 ,2 This is a laudable aim but the studies defining the efficacy of surveillance are generally of low quality and there is no readily applicable randomised controlled trial of surveillance in a western population. Recent evidence syntheses are conflicting and while meta-analysis of non-randomised case–control studies suggests benefits of surveillance this cannot be applied to patients with cirrhosis in general.3 ,4

    The study from Cross and coworkers in this issue of Frontline Gastroenterology used an online questionnaire …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles